Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20781655 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1FDPSMAPT | |
| SCHEMBL23733437 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1FDPSMAPT | |
| SCHEMBL23733446 | 0.91 | GNAI3 (0.34) | GNAI3GNAO1GNAI1MAPT | |
| SCHEMBL23733479 | 0.91 | GNAI3 (0.34) | GNAI3GNAO1GNAI1MAPT | |
| SCHEMBL23733462 | 0.91 | GNAI3 (0.38) | GNAI3GNAO1GNAI1FDPSMAPT | |
| SCHEMBL22962004 | 0.84 | GNAI3 (0.47) | GNAI3GNAO1GNAI1FDPS | |
| SCHEMBL22962144 | 0.84 | GNAI3 (0.47) | GNAI3GNAO1GNAI1FDPS | |
| SCHEMBL22962251 | 0.84 | GNAI3 (0.47) | GNAI3GNAO1GNAI1FDPS | |
| SCHEMBL22962335 | 0.84 | GNAI3 (0.47) | GNAI3GNAO1GNAI1FDPS | |
| SCHEMBL22962072 | 0.84 | GNAI3 (0.47) | GNAI3GNAO1GNAI1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | TLR7, TLR9, TLR4 | GNAI3 318/4885GNAO1 62/4885GNAI1 167/4885 |
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | GNAI3 1689/4885GNAO1 2690/4885GNAI1 1611/4885 |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | TLR7, TLR9, NOD1 | GNAI3 209/4885GNAO1 83/4885GNAI1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.